ADAR1 Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

ADAR1 Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$429K	Buy	751,141 +127,566	+20%	+$77.5K	0.03%	214
2025 Q4	$413K	Buy	623,575 +510,513	+452%	+$1.84M	0.03%	198
2025 Q3	$401K	Sell	113,062 -307,703	-73%	-$919K	0.04%	150
2025 Q2	$842K	Hold	420,765	–	–	0.13%	96
2025 Q1	$1.05M	Buy	420,765 +299,304	+246%	+$847K	0.2%	79
2024 Q4	$358K	Sell	121,461 -41,617	-26%	-$117K	0.07%	129
2024 Q3	$491K	Buy	+163,078	New	+$556K	0.08%	118
2024 Q2	–	Sell	-89,938	Closed	-$475K	–	316
2024 Q1	$475K	Sell	89,938 -155,564	-63%	-$748K	0.11%	85
2023 Q4	$1.26M	Buy	+245,502	New	+$929K	0.45%	38

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

ADAR1 Capital Management's VTGN Position: Q1 2026 in Review

ADAR1 Capital Management increased its VistaGen Therapeutics (VTGN) stake by 20% in Q1 2026, buying an estimated $77.5K and bringing the position to 751,141 shares worth $429K. The position accounts for 0.03% of the portfolio, ranked #214.

ADAR1 Capital Management first reported a position in VTGN in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.26M in Q4 2023. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

ADAR1 Capital Management held 751,141 shares of VistaGen Therapeutics worth $429K as of Q1 2026.
ADAR1 Capital Management bought 127,566 VistaGen Therapeutics shares in Q1 2026, an estimated $77.5K.
VistaGen Therapeutics made up 0.03% of ADAR1 Capital Management's portfolio in Q1 2026, its #214 holding.
ADAR1 Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 9 quarters since.
ADAR1 Capital Management's VistaGen Therapeutics position peaked at $1.26M in Q4 2023.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.